Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

dexrazoxane

A bisdioxopiperazine with iron-chelating, chemoprotective, cardioprotective, and antineoplastic activities. After hydrolysis to an active form that is similar to ethylenediaminetetraacetic acid (EDTA), dexrazoxane chelates iron, limiting the formation of free radical-generating anthracycline-iron complexes, which may minimize anthracycline-iron complex-mediated oxidative damage to cardiac and soft tissues. This agent also inhibits the catalytic activity of topoisomerase II, which may result in tumor cell growth inhibition.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:razoxane (+)-form
Code name:ADR 529
ADR-529
ADR529
ICRF 187
ICRF-187
ICRF187
Chemical structure:(+)-(S)-4,4'-(1-methyl-1,2-ethanediyl)di(2,6-piperazinedione)
2,6-piperazinedione, 4,4'-(1-methyl-1,2-ethanediyl)bis-,(S)-(9CI)
2,6-piperazinedione, 4,4'propylenedi-,(P)-(8CI)
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search